In September of 2000, the world's leading experts in MC met to discuss and present data at the "Year 2000 Working Conference on Mastocytosis," held in Vienna, Austria. Table 1 presents a uniform ...

The following is a summary of "Comparison of prognostic scores according to WHO classification in 170 patients with advanced ...

H2 antihistamines, such as ranitidine, cimetidine, or famotidine, are used to treat gastric hypersecretion and peptic ulcer disease associated with histamine release in mastocytosis (Worobec ...

As noted, mastocytosis can be very challenging to diagnose both due to the wide range of symptoms (which can be caused by a wide range of conditions) and due to other possible causes of facial ...

In Systemic Mastocytosis, What’s the Impact of Type ... in the serum of patients with systemic mastocytosis are markers of disease severity. These findings suggest that analyzing a panel of ...

Regardless of previous treatment or SM subtype, avapritinib continues to show efficacy and safety and a reduction in measures of disease burden. A new analysis of data from the PATHFINDER study ...

In Systemic Mastocytosis, What’s the Impact of Type ... in the serum of patients with systemic mastocytosis are markers of disease severity. These findings suggest that analyzing a panel of ...

Mutation-Adjusted Risk Score (MARS) and the specific subtype of advanced systemic mastocytosis (AdvSM) are highly predictive of overall survival and should therefore guide clinical decision-making, ...

Cogent Biosciences' uncertain competitive edge may compel investors to sit on the sidelines. Read more about the cautious ...

Sep. 20, 2024 — The incidence of stroke continues to increase for adults and children living with sickle cell disease (SCD) despite the Stroke Prevention Trial in ... Sep. 13, 2024 — When a ...